In this episode, Dennis Walker and Ash Ritter dive into the world of the infamous Amanita Muscaria mushroom, as well as learn about the wild desert apothecary of fungi and herbs that she researches and teaches about.
Similar Posts
This Week in Psychedelic Stocks [Big UPDATES ON MMEDF, CMPS, FTRPF, and ATAI]
Hello Psychedelic Investors! In this new segment entitled “This Week in Psychedelic Stocks”, we’ll see some news on MindMed (MMED / MMEDF), Compass Pathways (CMPS), Atai Life Sciences, and Field Trip Health (FTRPF/ FTRP).
We will cover the latest developments in the field writ large,
This means we will cover any stories that affect the all the companies in this field, as well as company specific developments.
Time Stamps
0:00 – Intro
0:56 – California Legalizing Psychedelics?
2:09 – Texas Legalizing Psychedelics?
3:33 – STOP LICKING TOADS DUDE
4:05 – MindMed Stock Updates (MMED / MMEDF)
9:13 – Compass Pathways Stock Updates (CMPS)
13:25 – Atai Life Sciences Update
17:05 – Field Trip Health Stock Updates (FTRPF/ FTRP)
I hope you guys found some value in this and I’ll keep you posted for more changes!
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
#MindMed #MindmedStock #PsychedelicStocks
Interview With Christi Myers
In this episode of the Psychedelic Spotlight Podcast, our Director of Content catches up with Christi Myers, founder and director of Flow Wellness. Christi discusses her career as a paramedic and how that translates into her work now, helping people heal traumas with ketamine therapy.
MindMed Launches DMT Clinical Trial (Joe Rogan Must Be Excited for MNMD)
MindMed Launches DMT Clinical Trial! Joe Rogan must be excited!
In this episode, we’ll discuss MindMed ‘s (NASDAQ: MNMD), ( NEO: MMED) announcement and why I’m personally excited about it.
As many of you know, of all the classic psychedelics, in many respects DMT, or dimethyltryptamine, is the most mysterious. When it is consumed, experiencers report being blasted off into an entirely new dimension of being or plane of existence, where you interact with autonomous, intelligent and wise beings. Those who have experienced this often claim that they return to our world with a sense of having learned important lessons, that are either too hard to put into words.
Now, we have no idea what is happening in a person’s brain while they are on DMT.
Is the experience completely physiological, for example has the DMT essentially initiated some sort of dream-like state while you are still conscious? Or is it more mystical than that?
Either way, the simplistic wisdom gained from “the spirit molecule”, as it is often called, has reportedly helped countless people beat their addictions, depression, anxiety and more.
Many people liken it to essentially “resetting your brain”.
Unfortunately, despite so much anecdotal evidence and entire sub cultures verging on the edge of religions dedicated to the substance, surprisingly little hard science has been done on the drug.
This is the reason behind my excitement today! MindMed announced initiation of phase 1 clinical trial of intravenous DMT.
Links:
MINDMED ANNOUNCES INITIATION OF PHASE 1 CLINICAL TRIAL OF INTRAVENOUS DMT:
https://thepsychedelicinvestor.com/2021/07/28/mindmed-announces-initiation-of-phase-1-clinical-trial-of-intravenous-dmt/
MindMed’s DMT Clinical Trial Specifications:
https://clinicaltrials.gov/ct2/show/NCT04353024?term=DMT&draw=2&rank=2
Previous DMT Studies:
https://www.nature.com/articles/s41598-020-61169-x
https://maps.org/research-archive/ayahuasca/Thomas_et_al_CDAR.pdf
Enjoy the episode!
Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com
Music from:
www.bensound.com
Video editing: @themyaholy
Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#MindMed #DMT #MNMD
Interview with James Lanthier, CEO of Mindset Pharma
CEO of Mindset Pharma, James Lanthier, gives us an overview of his company and the 4 new psychedelics they are creating. He also discusses some big breaking news!
Interview With Lauren Taus
In this episode of the Psychedelic Spotlight podcast we speak with Lauren Taus who is the Founder of INBodied Life, who’s focus is on integrating modern science and ancient wisdom to support transformation.